NASDAQ: MDWD - MediWound Ltd.

Yield per half year: +10.6%
Sector: Healthcare

Share chart MediWound Ltd.

Extended chart Simple chart
Financial Markets by TradingView

About

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

More details
The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка 0.0318
EBITDA 0.0056
Число акций ао 0.00901 млрд
P/E 22.3
P/S 2.61
P/BV 5.46
EV/EBITDA 13.76
Цена ао 15.56
ISIN IL0011316309
Сайт https://www.mediwound.com
Валюта usd
IPO date 2014-03-20
Sector Health Care
Industry Pharmaceuticals
Валюта отчета usd
Change price per day: -1.37% (16.82)
Change price per week: -0.7775% (16.72)
Change price per month: -2.35% (16.99)
Change price per 3 month: -15.36% (19.6)
Change price per half year: +10.6% (15)
Change price per year: +73.72% (9.55)
Change price per 3 year: +379.48% (3.46)
Change price per 5 year: +415.22% (3.22)
Change price per year to date: +110.27% (7.89)
All parameters

Underestimation

Title Value Grade
P/S 4.96 3
P/BV 2.36 6
P/E 0 0
EV/EBITDA -6.15 0
Total: 4.63

Efficiency

Title Value Grade
ROA, % -10.11 0
ROE, % -21.26 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.4727 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -41.24 0
Yield Ebitda, % -353.54 0
Yield EPS, % -177.81 0
Total: 0
More

Institutions Volume Share, %
Point72 Asset Management, L.P. 821500 6.44
Rosalind Advisors, Inc. 606751 4.76
DAFNA Capital Management, LLC 257653 2.02
Uniplan Investment Counsel, Inc. 145270 1.14
Wells Fargo & Company 132104 1.04
Yelin Lapidot Holdings Management Ltd. 125493 0.98
Sargent Investment Group, LLC 109194 0.86
Silverberg Bernstein Capital Management LLC 85184 0.67
Renaissance Technologies, LLC 55944 0.44
Sphera Funds Management Ltd. 48980 0.38

ETF Share, % Profitability for 1 year, % Dividends, %
ProShares Hedge Replication ETF 0.00087 5.9237999659878 1.47892
ARK Israel Innovative Technology ETF 1.84994 15.892557358702 1.21688
ProShares UltraPro Russell2000 0.00304 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.01 39.350070246167 0.60264
Vanguard Russell 2000 ETF 0.01 35.648084105685 1.48801



Head Job title Payment Year of birth
Mr. Ofer Gonen B.Sc. Chief Executive Officer 649k 1973 (51 year)
Dr. Lior Rosenberg M.D. Co-Founder 727k 1946 (78 years)
Dr. Ety Klinger MBA, Ph.D. Chief Research & Development Officer 377k 1962 (62 years)
Ms. Hani Luxenburg Chief Financial Officer 235k 1973 (51 year)
Dr. Shmulik Hess Ph.D. COO & Chief Commercial Officer N/A 1973 (51 year)
Mr. Yaron Meyer Adv. Executive VP, General Counsel & Corporate Secretary 299k 1979 (45 years)
Mr. Barry J. Wolfenson Executive Vice President of Strategy & Corporate Development N/A 1967 (57 years)
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. Chief Medical Officer N/A 1950 (74 years)
Dr. Liron Gal Executive Director of Manufacturing Science & Technology

Address: Israel, Yavne, 42 Hayarkon Street - open in Google maps, open in Yandex maps
Website: https://www.mediwound.com